Patients who cease pubertal progression with GnRH agonist therapy resume their pubertal progression after cessation of therapy. It is appropriate to use GnRH in a patient who is shown to have progressive central precocious puberty that causes advancing bone age and physical development, or in girls who have started premature menstrual periods. Medroxyprogesterone acetate and cyproterone acetate were used in the past to treat central precocious puberty but have rarely been used since the advent of GnRH agonist therapy.
